Table 5. Predictors of virologic suppression <400 copies/ml 4–12 months after restarting NNRTI-based ART.^a .

		Univariable analysis			Multivariable analysis
		OR	95% CI	P-value	OR	95% CI	P-value
Gender	Female	0.60	0.19, 1.85	0.38	0.41	0.10, 1.68	0.22
	Male	1.00	–		1.00	–
Age	Each 5 years older	1.04	0.78, 1.39	0.79	1.09	0.71, 1.68	0.70
Time on ART pre-interruption	Each year longer	0.91	0.80, 1.03	0.15	0.89	0.75, 1.07	0.21
HIV-1 RNA load at interruptionb	<50 copies/ml	1.09	0.38, 3.15	0.87	1.00	0.27, 3.72	0.99
	Other	1.00	–		1.00	–
CD4 count at interruption	Each 50 cells/mm3 higher	1.05	0.91, 1.19	0.52	1.06	0.89, 1.27	0.50
Time to restarting ART	Each week longer	1.01	0.99, 1.04	0.21	1.02	0.99, 1.06	0.11
NNRTI restarted	Nevirapine	0.55	0.19, 1.61	0.28	0.55	0.15, 2.09	0.38
	Efavirenz	1.00	–		1.00	–
Interruption modality	Staggered/Switched	1.83	0.63, 5.34	0.27	2.62	0.60, 11.38	0.20
	Simultaneous	1.00	–		2.62	–	0.20
Resistance-associated mutations	NNRTI	0.22	0.06, 0.84	0.03	0.18	0.03, 0.89	0.04
	NRTI only	0.24	0.06, 1.01		0.17	0.03, 1.15
	None	1.00	–		1.00	–

^aThe analysis included 90 patients who restarted NNRTI-based ART without a protease inhibitor and had at least one viral load measurement in the 4–12 months after re-starting therapy.

^bAs noted above some patients had the viral load measured by assays with a lower limit of quantification of either 75 or 400 copies/ml. NNRTI = non-nucleoside reverse transcriptase inhibitor; ART = antiretroviral therapy; OR = Odds ratio; CI = confidence interval.